NCT03512171 - Decision Making Study in Young and Middle-Aged Adults: Part II | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 15, 2018

Study Completion Date

May 15, 2018

Conditions

Healthy Adults

Interventions

DRUG

Dextroamphetamine

One oral dose of dextroamphetamine (0.43mg/kg). The amphetamine is given in order to induce the release of their own dopamine for study with positron emission tomography (PET).

DRUG

Placebo

One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).

DIAGNOSTIC_TEST

[18F]Fallypride

Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)

DIAGNOSTIC_TEST

[18F]-FE-PE2I

Radioligand for measuring dopamine transporters with positron emission tomography (PET)

Trial Locations (1)

37203

Zald Affective Neuroscience Lab- Vanderbilt University, Nashville